← BridgeBio Pharma overview

BridgeBio Pharma vs Regeneron Pharmaceuticals: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

BridgeBio Pharma Inc (BBIO)

Q3 2026
▲3

BridgeBio Soars on Rival's Failure and Strong Attruby Data

  • AstraZeneca's ATTR-CM failure clears path for Attruby AstraZeneca's heart drug failed, removing a key competitor for BridgeBio's Attruby. Shares jumped 15% to a 52-week high as investors saw a clearer market for the treatment.

    This was the main catalyst for the stock's rise in the quarter.

  • Attruby shows kidney benefits and strong revenue growth Attruby demonstrated kidney-protective benefits, and Q2 revenue surged 120% to $243.7 million. Imaging data also hinted at possible cardiac improvement, though that finding is exploratory.

    These clinical and financial results reinforced the growth story.

  • Pipeline advances with three late-stage drugs nearing launch Three late-stage drugs are close to launch, two under FDA Priority Review. Infigratinib's Phase 3 data were published in NEJM, boosting confidence in the company's pipeline.

    Pipeline progress supports future revenue potential.

  • Capital raise and Medicaid pricing deal create trade-offs BridgeBio raised $1 billion in preferred equity, strengthening its balance sheet. However, a Medicaid most-favored-nation pricing deal could reduce future U.S. revenue per prescription.

    The capital boost is positive, but the pricing deal poses a risk to future profits.

August 2026
▲3▼1

Attruby Sales Boom, Three Launches Near, But Medicaid Price Cuts Loom

  • Attruby sales more than tripled, driving 120% revenue growth Second-quarter revenue hit $243.7 million, up 120% from a year ago, as Attruby U.S. sales more than tripled to $222.4 million. The drug is gaining first-line share in ATTR-CM, and real-world data show fewer heart hospitalizations than the rival tafamidis. More sales mean more cash to fund the business, which supports the stock.

    This is the core commercial engine behind BBIO's revenue growth and the main reason the stock has risen.

  • Three pipeline drugs near launch, two with FDA Priority Review All three late-stage programs have been filed with the FDA. BBP-418 for LGMD2I/R9 has a decision date of Nov 27, 2026, and encaleret for ADH1 has one of May 8, 2027, both under Priority Review; oral infigratinib for achondroplasia targets a mid-2027 launch. New approvals would add revenue streams and reduce reliance on Attruby.

    Pipeline launches are the next major growth catalyst and explain why investors look past current losses.

  • New heart-imaging data suggest acoramidis may reverse cardiac damage In the Phase 3 ATTRibute-CM study, 54% of acoramidis-treated patients had meaningful improvement in heart pumping function at 30 months versus 20% on placebo, and patients gained 38 more days alive outside the hospital. If confirmed, this could differentiate Attruby from rivals. The company cautions these are exploratory analyses, not proof of reversal.

    This is fresh clinical evidence that could strengthen Attruby's competitive position and long-term sales.

  • BridgeBio signed a Medicaid most-favored-nation pricing deal BridgeBio is one of nine mid-sized drugmakers agreeing to match U.S. Medicaid prices to lower prices in other developed countries, in exchange for relief from import tariffs on ingredients. This could reduce future U.S. revenue per prescription, though state participation is optional and the full financial impact is not yet clear.

    This is a new regulatory overhang that could pressure pricing and is a real counterweight to the positive sales story.

Latest
▲3▼1

Attruby Sales Boom, Three Launches Near, But Medicaid Price Cuts Loom

  • Attruby sales more than tripled, driving 120% revenue growth Second-quarter revenue hit $243.7 million, up 120% from a year ago, as Attruby U.S. sales more than tripled to $222.4 million. The drug is gaining first-line share in ATTR-CM, and real-world data show fewer heart hospitalizations than the rival tafamidis. More sales mean more cash to fund the business, which supports the stock.

    This is the core commercial engine behind BBIO's revenue growth and the main reason the stock has risen.

  • Three pipeline drugs near launch, two with FDA Priority Review All three late-stage programs have been filed with the FDA. BBP-418 for LGMD2I/R9 has a decision date of Nov 27, 2026, and encaleret for ADH1 has one of May 8, 2027, both under Priority Review; oral infigratinib for achondroplasia targets a mid-2027 launch. New approvals would add revenue streams and reduce reliance on Attruby.

    Pipeline launches are the next major growth catalyst and explain why investors look past current losses.

  • New heart-imaging data suggest acoramidis may reverse cardiac damage In the Phase 3 ATTRibute-CM study, 54% of acoramidis-treated patients had meaningful improvement in heart pumping function at 30 months versus 20% on placebo, and patients gained 38 more days alive outside the hospital. If confirmed, this could differentiate Attruby from rivals. The company cautions these are exploratory analyses, not proof of reversal.

    This is fresh clinical evidence that could strengthen Attruby's competitive position and long-term sales.

  • BridgeBio signed a Medicaid most-favored-nation pricing deal BridgeBio is one of nine mid-sized drugmakers agreeing to match U.S. Medicaid prices to lower prices in other developed countries, in exchange for relief from import tariffs on ingredients. This could reduce future U.S. revenue per prescription, though state participation is optional and the full financial impact is not yet clear.

    This is a new regulatory overhang that could pressure pricing and is a real counterweight to the positive sales story.

July 2026
▲4

BridgeBio's Attruby Strengthens as Rival Fails and Pipeline Advances

  • Attruby's competitive position strengthens after AstraZeneca's ATTR-CM failure AstraZeneca's Wainua failed a phase III ATTR-CM trial, removing a potential rival. BridgeBio's Attruby, already approved, gained a clearer path in a market worth over $20 billion. The stock jumped 15% to a 52-week high, adding $2.3 billion in market value.

    This is the biggest new driver: a rival's failure directly boosts Attruby's outlook and sent BBIO to a 52-week high.

  • New data shows Attruby has unique kidney-protective benefits Post-hoc analyses showed acoramidis (Attruby) directly protects kidneys in ATTR-CM patients, a benefit not seen with other approved therapies. This could make Attruby a preferred treatment, supporting sales growth and a higher stock price.

    This new clinical evidence differentiates Attruby from competitors and could drive future demand.

  • BridgeBio raises $1 billion in preferred equity to fund launches BridgeBio secured up to $1 billion from Sixth Street and KKR to accelerate launches of Attruby and three potential new drugs. The cash strengthens the balance sheet, reducing financing risk and supporting growth, which is positive for the stock.

    This new capital raise gives BridgeBio funds to execute its launch plans, a key positive for future revenue.

  • Infigratinib Phase 3 data published in NEJM, supporting regulatory submission Positive Phase 3 results for oral infigratinib in achondroplasia were published in the New England Journal of Medicine, showing the largest height velocity improvement in any such trial. BridgeBio plans to file for FDA approval in Q3 2026, with launch expected in 2027.

    This new data publication validates a key pipeline asset and brings a potential new blockbuster closer to market.

▲4

BridgeBio's Attruby Strengthens as Rival Fails and Pipeline Advances

  • Attruby's competitive position strengthens after AstraZeneca's ATTR-CM failure AstraZeneca's Wainua failed a phase III ATTR-CM trial, removing a potential rival. BridgeBio's Attruby, already approved, gained a clearer path in a market worth over $20 billion. The stock jumped 15% to a 52-week high, adding $2.3 billion in market value.

    This is the biggest new driver: a rival's failure directly boosts Attruby's outlook and sent BBIO to a 52-week high.

  • New data shows Attruby has unique kidney-protective benefits Post-hoc analyses showed acoramidis (Attruby) directly protects kidneys in ATTR-CM patients, a benefit not seen with other approved therapies. This could make Attruby a preferred treatment, supporting sales growth and a higher stock price.

    This new clinical evidence differentiates Attruby from competitors and could drive future demand.

  • BridgeBio raises $1 billion in preferred equity to fund launches BridgeBio secured up to $1 billion from Sixth Street and KKR to accelerate launches of Attruby and three potential new drugs. The cash strengthens the balance sheet, reducing financing risk and supporting growth, which is positive for the stock.

    This new capital raise gives BridgeBio funds to execute its launch plans, a key positive for future revenue.

  • Infigratinib Phase 3 data published in NEJM, supporting regulatory submission Positive Phase 3 results for oral infigratinib in achondroplasia were published in the New England Journal of Medicine, showing the largest height velocity improvement in any such trial. BridgeBio plans to file for FDA approval in Q3 2026, with launch expected in 2027.

    This new data publication validates a key pipeline asset and brings a potential new blockbuster closer to market.

Regeneron Pharmaceuticals Inc (REGN)

Q3 2026
▲2▼2

Regeneron's Q3: pipeline wins, Sanofi deal, but melanoma setback

  • Strong Q2 results and pipeline progress Regeneron reported Q2 revenue up 17% to $4.29 billion, received FDA priority review for cemdisiran in myasthenia gravis, and won approval for Pasatru in FOP disease. These advances support future growth.

    These positive developments drove investor optimism and supported the stock.

  • Expanded Sanofi deal and obesity drug data Regeneron expanded its Sanofi partnership with $1 billion upfront and four pipeline therapies. Its obesity drug trevogrumab preserved about 70% of muscle loss in a Phase 2 trial, showing promise in a large market.

    The deal and trial data are new positive catalysts for Regeneron's growth outlook.

  • Failed melanoma trial and lawsuits A failed melanoma trial led to class-action lawsuits and an $11 billion market-value loss. This setback raised concerns about pipeline execution and weighed on the stock.

    This was a major negative event that hurt investor confidence and the share price.

  • Eylea competition and Sanofi deal disappointment Eylea faces biosimilar and competitive threats, notably Kodiak's less-frequent-dosing eye drug. The Sanofi deal left Dupixent profit-sharing unchanged, disappointing some investors and briefly pressuring shares.

    These competitive and deal-related concerns created headwinds for the stock.

August 2026
▲2▼1

Regeneron's strong Q2 and pipeline wins offset by legal and competitive risks

  • Strong Q2 earnings and margin improvement Regeneron beat Q2 estimates with revenue up 17% to $4.29 billion, driven by Dupixent and high-dose Eylea. Repaying the Sanofi Development Balance should improve margins, and buybacks and dividends support shareholder value.

    This point explains the positive financial performance that drove the stock during the period.

  • Pipeline progress and new Sanofi deal FDA approval of Pasatru for rare FOP disease validates Regeneron's drug platform. A new Sanofi deal adds $1 billion upfront and four pipeline therapies, strengthening the pipeline and providing external validation.

    This point highlights key pipeline and partnership developments that boosted investor sentiment.

  • Pipeline uncertainty and Eylea competition Mixed melanoma trial results and increasing competition for Eylea add pipeline uncertainty. These factors offset strong commercial performance and contribute to a balanced but cautious outlook.

    This point explains the competitive and pipeline challenges that acted as a counterweight to positive developments.

Latest
▲2▼2

Regeneron's Sanofi deal and pipeline progress offset by Eylea competition and lawsuits

  • Sanofi deal expands pipeline with $1B upfront Regeneron and Sanofi agreed to jointly develop four long-acting immunology therapies, led by REGN20423, in a deal worth up to $8 billion including $1 billion upfront. This brings cash and pipeline growth, supporting future revenue and the stock.

    This is a major new partnership that directly boosts Regeneron's pipeline and cash, a key positive driver.

  • Securities class action lawsuits weigh on sentiment Multiple law firms filed class actions alleging Regeneron made false statements about its Fianlimab-Libtayo trial, causing investor losses. The legal uncertainty and potential reputational damage pressure the stock, though the company denies wrongdoing.

    These lawsuits are a new negative overhang that could affect investor confidence and lead to financial penalties.

  • Mixed melanoma trial results lead to pullback Regeneron's melanoma drug trial produced mixed results, causing shares to give back some gains. This setback raises doubts about the drug's potential and adds to pipeline uncertainty, weighing on the stock.

    This is a new clinical setback that directly impacts Regeneron's oncology pipeline and investor expectations.

  • Buybacks and dividend support shareholder value Regeneron confirmed its quarterly dividend, updated on share repurchases, and reported Q2 results. With the stock trading below fair value estimates, these capital returns and pipeline progress support the shares.

    This shows management's commitment to returning cash and the stock's valuation appeal, a positive for investors.

September 2026
▲3▼1

Regeneron's pipeline wins and Sanofi deal offset by Eylea competition

  • Sanofi alliance expansion brings $1B upfront and pipeline growth Sanofi will pay Regeneron $1 billion upfront plus up to $7 billion in milestones for four new antibodies, expanding the partnership that made Dupixent. This boosts Regeneron's cash and pipeline, but the deal left Dupixent profit-sharing unchanged, disappointing some investors and causing a 4% share drop.

    This is the period's biggest capital and pipeline event, directly affecting Regeneron's finances and investor sentiment.

  • Trevogrumab preserves muscle in Phase 2 obesity trial Regeneron's trevogrumab preserved about 70% of muscle loss caused by semaglutide in a Phase 2 trial. This opens a potential new obesity treatment, a large market, and shows Regeneron's research engine is producing promising results, which supports the stock.

    A positive clinical readout in a major new market area is a key driver of future growth expectations.

  • Kodiak eye drug matches Eylea with less frequent dosing Kodiak Sciences reported Phase 3 data showing its eye drugs matched Eylea's vision results with dosing every six months versus Eylea's eight weeks. This threatens Regeneron's key Eylea franchise, which is already facing biosimilar competition, and could pressure future sales.

    Eylea is a major revenue source, and new competition with better convenience could erode Regeneron's market share.

  • Pozelimab-cemdisiran highlighted as top emerging PNH therapy An analyst forecast named Regeneron's pozelimab plus cemdisiran as the emerging PNH therapy expected to generate the highest revenue, with Phase 3 results due late 2026 or early 2027. This supports hopes for a new blockbuster beyond current drugs.

    It points to a future growth driver and validates Regeneron's pipeline in a rare disease market.

▲3▼1

Regeneron's pipeline wins and Sanofi deal offset by Eylea competition

  • Sanofi alliance expansion brings $1B upfront and pipeline growth Sanofi will pay Regeneron $1 billion upfront plus up to $7 billion in milestones for four new antibodies, expanding the partnership that made Dupixent. This boosts Regeneron's cash and pipeline, but the deal left Dupixent profit-sharing unchanged, disappointing some investors and causing a 4% share drop.

    This is the period's biggest capital and pipeline event, directly affecting Regeneron's finances and investor sentiment.

  • Trevogrumab preserves muscle in Phase 2 obesity trial Regeneron's trevogrumab preserved about 70% of muscle loss caused by semaglutide in a Phase 2 trial. This opens a potential new obesity treatment, a large market, and shows Regeneron's research engine is producing promising results, which supports the stock.

    A positive clinical readout in a major new market area is a key driver of future growth expectations.

  • Kodiak eye drug matches Eylea with less frequent dosing Kodiak Sciences reported Phase 3 data showing its eye drugs matched Eylea's vision results with dosing every six months versus Eylea's eight weeks. This threatens Regeneron's key Eylea franchise, which is already facing biosimilar competition, and could pressure future sales.

    Eylea is a major revenue source, and new competition with better convenience could erode Regeneron's market share.

  • Pozelimab-cemdisiran highlighted as top emerging PNH therapy An analyst forecast named Regeneron's pozelimab plus cemdisiran as the emerging PNH therapy expected to generate the highest revenue, with Phase 3 results due late 2026 or early 2027. This supports hopes for a new blockbuster beyond current drugs.

    It points to a future growth driver and validates Regeneron's pipeline in a rare disease market.

▲3▼1

Regeneron beats on Dupixent/Eylea, wins rare-disease approval, faces lawsuit

  • Q2 beat on Dupixent and high-dose Eylea Regeneron beat second-quarter estimates: revenue rose 17% to $4.29 billion and adjusted profit was $14.29 a share. Dupixent sales jumped 38% to about $6 billion, and U.S. high-dose Eylea sales rose 52%. Strong demand for these key drugs lifts profit and supports the stock.

    This is the period's biggest positive fundamental driver of REGN's value.

  • Sanofi repayment improves margins Regeneron fully repaid the Sanofi Development Balance. An RBC analyst said this should improve margins and make second-half numbers look much better. Paying off this obligation frees up cash and boosts future profit, a positive for the stock.

    It is a concrete capital event that improves future profitability.

  • FDA approves Pasatru for rare FOP disease The FDA approved Pasatru (garetosmab) for fibrodysplasia ossificans progressiva, a rare bone disease, based on a Phase 3 trial showing 90% fewer new lesions. The patient group is tiny, so near-term sales are modest, but it proves Regeneron's drug platform still produces new approved medicines.

    A new FDA approval is a fresh product and pipeline milestone for REGN.

  • Securities class action over failed melanoma trial A securities class action alleges Regeneron misled investors about the Phase 3 Fianlimab-Libtayo melanoma trial, which failed its main goal and wiped out $11 billion in market value. The lead plaintiff deadline is September 14. Legal costs and uncertainty weigh on the stock.

    This is the main negative overhang on REGN this period.

July 2026
▼2▲1

Regeneron's pipeline setbacks trigger lawsuits, but cemdisiran advances

  • Cemdisiran regulatory progress FDA granted Priority Review and EMA accepted filings for cemdisiran in generalized myasthenia gravis. If approved, it would be the first siRNA treatment and only subcutaneous option dosed four times a year, opening a new revenue stream. FDA decision expected November 2026.

    This is a new positive regulatory catalyst that could drive future revenue and investor optimism.

  • Failed melanoma trial and securities lawsuits Regeneron faces multiple class action lawsuits alleging it misled investors about its Phase 3 Fianlimab-Libtayo melanoma trial, which failed to meet its primary endpoint. The trial failure wiped out $11 billion in market value, and the lawsuits create legal overhang and reputational risk.

    This is a new negative development that directly impacts Regeneron's stock through legal uncertainty and investor confidence.

  • Pipeline setbacks and mixed trial results Longleaf Partners Fund reported Regeneron was a Q2 detractor after disappointing trial results for a pipeline drug. The fund noted only one of three key pipeline readouts succeeded, below expectations. This highlights execution risk in Regeneron's drug development, weighing on sentiment.

    This new analyst commentary underscores pipeline challenges that could pressure the stock.

▼2▲1

Regeneron's pipeline setbacks trigger lawsuits, but cemdisiran advances

  • Cemdisiran regulatory progress FDA granted Priority Review and EMA accepted filings for cemdisiran in generalized myasthenia gravis. If approved, it would be the first siRNA treatment and only subcutaneous option dosed four times a year, opening a new revenue stream. FDA decision expected November 2026.

    This is a new positive regulatory catalyst that could drive future revenue and investor optimism.

  • Failed melanoma trial and securities lawsuits Regeneron faces multiple class action lawsuits alleging it misled investors about its Phase 3 Fianlimab-Libtayo melanoma trial, which failed to meet its primary endpoint. The trial failure wiped out $11 billion in market value, and the lawsuits create legal overhang and reputational risk.

    This is a new negative development that directly impacts Regeneron's stock through legal uncertainty and investor confidence.

  • Pipeline setbacks and mixed trial results Longleaf Partners Fund reported Regeneron was a Q2 detractor after disappointing trial results for a pipeline drug. The fund noted only one of three key pipeline readouts succeeded, below expectations. This highlights execution risk in Regeneron's drug development, weighing on sentiment.

    This new analyst commentary underscores pipeline challenges that could pressure the stock.

Q2 2026
▲3▼1

Regeneron advances new drugs as Dupixent soars and AbbVie threat looms

  • CytomX collaboration expands cancer pipeline Regeneron expanded its cancer drug partnership with CytomX, paying $37 million upfront and potentially up to $4 billion in milestones. This gives Regeneron access to new technology for next-generation cancer therapies, which could boost future revenue and growth prospects.

    This is a new deal that adds to Regeneron's pipeline and potential future earnings.

  • Dupixent sales surge 30.8% Sanofi reported that Dupixent, co-developed with Regeneron, generated €4.17 billion in first-quarter sales, up 30.8% from a year ago. This strong growth directly boosts Regeneron's revenue and profit, as Regeneron shares in the profits.

    Dupixent is a major revenue driver for Regeneron, and its strong sales growth directly impacts Regeneron's financial performance.

  • FDA and EMA accept cemdisiran filings Regeneron's new drug cemdisiran for generalized myasthenia gravis was accepted for review by the FDA and EMA. The FDA granted Priority Review with a decision expected by November 2026. If approved, it could be a first-in-class treatment, adding a new revenue stream.

    This regulatory milestone brings Regeneron closer to launching a new drug, which could drive future sales.

  • AbbVie acquires Apogee, increasing competition AbbVie agreed to buy Apogee Therapeutics for $10.9 billion, gaining a potential competitor to Regeneron's Dupixent. This could pressure Dupixent's market share in inflammatory diseases like atopic dermatitis and asthma, posing a long-term risk to Regeneron's revenue.

    This is a new competitive threat that could impact Regeneron's key product, Dupixent.

June 2026
▲3▼1

Regeneron advances new drugs as Dupixent soars and AbbVie threat looms

  • CytomX collaboration expands cancer pipeline Regeneron expanded its cancer drug partnership with CytomX, paying $37 million upfront and potentially up to $4 billion in milestones. This gives Regeneron access to new technology for next-generation cancer therapies, which could boost future revenue and growth prospects.

    This is a new deal that adds to Regeneron's pipeline and potential future earnings.

  • Dupixent sales surge 30.8% Sanofi reported that Dupixent, co-developed with Regeneron, generated €4.17 billion in first-quarter sales, up 30.8% from a year ago. This strong growth directly boosts Regeneron's revenue and profit, as Regeneron shares in the profits.

    Dupixent is a major revenue driver for Regeneron, and its strong sales growth directly impacts Regeneron's financial performance.

  • FDA and EMA accept cemdisiran filings Regeneron's new drug cemdisiran for generalized myasthenia gravis was accepted for review by the FDA and EMA. The FDA granted Priority Review with a decision expected by November 2026. If approved, it could be a first-in-class treatment, adding a new revenue stream.

    This regulatory milestone brings Regeneron closer to launching a new drug, which could drive future sales.

  • AbbVie acquires Apogee, increasing competition AbbVie agreed to buy Apogee Therapeutics for $10.9 billion, gaining a potential competitor to Regeneron's Dupixent. This could pressure Dupixent's market share in inflammatory diseases like atopic dermatitis and asthma, posing a long-term risk to Regeneron's revenue.

    This is a new competitive threat that could impact Regeneron's key product, Dupixent.

▲3▼1

Regeneron advances new drugs as Dupixent soars and AbbVie threat looms

  • CytomX collaboration expands cancer pipeline Regeneron expanded its cancer drug partnership with CytomX, paying $37 million upfront and potentially up to $4 billion in milestones. This gives Regeneron access to new technology for next-generation cancer therapies, which could boost future revenue and growth prospects.

    This is a new deal that adds to Regeneron's pipeline and potential future earnings.

  • Dupixent sales surge 30.8% Sanofi reported that Dupixent, co-developed with Regeneron, generated €4.17 billion in first-quarter sales, up 30.8% from a year ago. This strong growth directly boosts Regeneron's revenue and profit, as Regeneron shares in the profits.

    Dupixent is a major revenue driver for Regeneron, and its strong sales growth directly impacts Regeneron's financial performance.

  • FDA and EMA accept cemdisiran filings Regeneron's new drug cemdisiran for generalized myasthenia gravis was accepted for review by the FDA and EMA. The FDA granted Priority Review with a decision expected by November 2026. If approved, it could be a first-in-class treatment, adding a new revenue stream.

    This regulatory milestone brings Regeneron closer to launching a new drug, which could drive future sales.

  • AbbVie acquires Apogee, increasing competition AbbVie agreed to buy Apogee Therapeutics for $10.9 billion, gaining a potential competitor to Regeneron's Dupixent. This could pressure Dupixent's market share in inflammatory diseases like atopic dermatitis and asthma, posing a long-term risk to Regeneron's revenue.

    This is a new competitive threat that could impact Regeneron's key product, Dupixent.